tbuckley/cabot-search huggingface dataset:
The European Cancer Patient Coalition’s white policy paper on the value of innovation in oncology
Authors: L. Makaroff, F. De Lorenzo, K. Apostolidis, J. Pelouchova, A. Winterbottom, S. Chrostowski, D. Cimpoeru, N. Bolanos Fernandez, A. Rek, I. Manneh-Vangramberen, L. Baker, F. Florindi
Journal: Annals of Oncology (2017)
A gene signature of chemo-immunization to predict outcome in patients with triple negative breast cancer treated with anthracycline-based neoadjuvant chemotherapy
Authors: C. Criscitiello, M.A. Bayar, G. Curigliano, F. Symmans, C. Desmedt, H. Bonnefoi, B. Sinn, G. Pruneri, C. Vicier, J-Y. Pierga, C. Denkert, S. Loibl, C. Sotiriou, S. Michiels, F. André
Journal: Annals of Oncology (2017)
GW28-e1227 Efficacy of Short-term Antiarrhythmic Drugs Use after Catheter Ablation of Atrial Fibrillation - A Systematic Review with Meta-analyses and Trial Sequential Analyses of Randomized Controlled Trials
Authors: Weijie Chen, Hang Liu, Zhiyu Ling, Yanping Xu, Jinqi Fan, Huaan Du, Peilin Xiao, Li Su, Zengzhang Liu, Xianbin Lan, Bernhard Zrenner, Yuehui Yin
Journal: Journal of the American College of Cardiology (2017)
Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
Authors: Scott Gettinger, Jungmin Choi, Katherine Hastings, Anna Truini, Ila Datar, Ryan Sowell, Anna Wurtz, Weilai Dong, Guoping Cai, Mary Ann Melnick, Victor Y. Du, Joseph Schlessinger, Sarah B. Goldberg, Anne Chiang, Miguel F. Sanmamed, Ignacio Melero, Jackeline Agorreta, Luis M. Montuenga, Richard Lifton, Soldano Ferrone, Paula Kavathas, David L. Rimm, Susan M. Kaech, Kurt Schalper, Roy S. Herbst, Katerina Politi
Journal: Cancer Discovery (2017)

Mechanisms of acquired resistance to immune checkpoint inhibitors (ICI) are poorly understood. We leveraged a collection of 14 ICI-resistant lung cancer samples to investigate whether alterations in genes encoding HLA Class I antigen processing and presentation machinery (APM) components or interferon signaling play a role in acquired resistance to PD-1 or PD-L1 antagonistic antibodies. Recurrent mutations or copy-number changes were not detected in our cohort. In one case, we found acquired homozygous loss of B2M that caused lack of cell-surface HLA Class I expression in the tumor and a matched patient-derived xenograft (PDX). Downregulation of B2M was also found in two additional PDXs established from ICI-resistant tumors. CRISPR-mediated knockout of B2m in an immunocompetent lung cancer mouse model conferred resistance to PD-1 blockade in vivo, proving its role in resistance to ICIs. These results indicate that HLA Class I APM disruption can mediate escape from ICIs in lung cancer.Significance: As programmed death 1 axis inhibitors are becoming more established in standard treatment algorithms for diverse malignancies, acquired resistance to these therapies is increasingly being encountered. Here, we found that defective antigen processing and presentation can serve as a mechanism of such resistance in lung cancer. Cancer Discov; 7(12); 1420-35. ©2017 AACR.This article is highlighted in the In This Issue feature, p. 1355.
GW28-e0464 THE COUNT OF DIFFERENT SUBPOPULATIONS OF MONOCYTES AND CIRCULATING ENDOTHELIAL CELLS IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION AND TYPE 2 DIABETES MELLITUS
Authors: Galina Kukharchik, Olga Lebedeva, Alexey Ermakov, Larisa Gaikovaya, Viktoria Dmitrieva, Olga Abramova
Journal: Journal of the American College of Cardiology (2017)
What is the role of whole brain radiation therapy (WBRT) and high-dose cytarabine (Ara-C) as consolidation treatment after initial chemotherapy for primary CNS lymphoma (PCNSL)?
Authors: M. Ekenel, F. M. Iwamoto, L. S. Ben Porat, K. S. Panageas, J. Yahalom, L. M. DeAngelis, L. E. Abrey
Journal: Journal of Clinical Oncology (2007)

2013 Background: Optimal management of PCNSL is not defined. To date the best outcomes have been achieved by combined modality therapy using methotrexate (MTX)-based chemotherapy and WBRT. However, WBRT carries a significant risk of neurotoxicity and may not be required in all patients. Methods: We retrospectively analyzed the data of 122 patients who had complete response (CR) after initial chemotherapy, from a total of 338 PCNSL patients treated in our institution since 1986. Descriptive variables including sex, age, KPS at diagnosis, histology, and extent of CNS involvement were reported. We specifically studied the benefit of consolidation therapy with WBRT and/or high dose Ara-C on OS and PFS. Results: The median age was 60 (19–89) years and a median KPS was 70. Men constituted 57% of the patients. Median follow up was 30 months. Histologically, 83% had diffuse large B cell lymphoma. Ocular and CSF involvements were 13%, and 27%, respectively. Most patients received MTX-based regimens (96%). Five-year OS was 43% and five-year PFS was 50% for all patients. There was no significant difference in OS, between patients who received consolidation therapy with Ara-C (n=35), WBRT (n=12), Ara-C + WBRT (n=28), or no consolidation (n=42) [data from 5 patients are missing]. There was a trend towards improved disease control for patients treated with WBRT; however, these patients were also younger than the other groups. Risk of neurotoxicity was significantly higher in patients who received WBRT (p=0.005). Conclusions: Consolidation therapy does not clearly improve survival in PCNSL patients with a CR to initial treatment. However other important prognostic factors including age and KPS may have been used in the decision making related to consolidation therapy. [Table: see text] No significant financial relationships to disclose.
Circulating microRNA‐132 levels improve risk prediction for heart failure hospitalization in patients with chronic heart failure
Authors: Serge Masson, Sandor Batkai, Julia Beermann, Christian Bär, Angelika Pfanne, Sabrina Thum, Michela Magnoli, Giovanna Balconi, Gian Luigi Nicolosi, Luigi Tavazzi, Roberto Latini, Thomas Thum
Journal: European Journal of Heart Failure (2017)
OHERA: A real world study of cardiac events in > 3700 patients with her2-positive early breast cancer treated with trastuzumab: Final analysis
Authors: E. Lidbrink, J. Erfan, E. Chmielowska, B. Otremba, A. Bouhlel, S. Lauer, M. Liste Hermoso, E. Nüesch, M. Shing, V. Misra
Journal: Annals of Oncology (2017)
Tumor-stroma interactions as a determinant of drug resistance in BRAF-mut melanoma
Authors: I. Falcone, R. Loria, U. Cesta Incani, L. Ciuffreda, C. Bazzichetto, F. Conciatori, B. Bellei, D. Kovacs, M. Picardo, R. Falcioni, M. Milella
Journal: Annals of Oncology (2017)
Abstract 17152: Frequency and Management of Major Bleeding in Atrial Fibrillation Patients Treated With Warfarin and Non-vitamin K Oral Anticoagulants in Community Practice: Results From the ORBIT-AF II Registry
Authors: Benjamin A Steinberg, DaJuanicia N Simon, Laine Thomas, Jack Ansell, Gregg C Fonarow, Bernard J Gersh, Peter R Kowey, Kenneth W Mahaffey, Eric D Peterson, Jonathan P Piccini
Journal: Circulation (2015)

Background: Non-vitamin K oral anticoagulants (NOACs) are effective at preventing stroke in patients with atrial fibrillation (AF). However, little is known about the frequency of major bleeds on NOACs and how these events are managed in clinical practice. Methods: We assessed the rates, management, and outcomes of ISTH major bleeding events among AF patients in the ORBIT-AF II registry (mean follow-up 213 days). Results: Overall, 103 patients experienced 110 major bleeding events during follow-up n=90/4986 (1.8%) on NOAC, and n=20/1320 (1.5%) on warfarin. Patients with bleeding events on NOAC were slightly younger than those on warfarin (median age 76 vs. 80; p=0.2). Among mutually-exclusive bleeding types, intracranial bleeding was more common in warfarin treated patients than NOAC-treated (15% vs 6.7%), whereas GI bleeding was more common on NOACs (56% vs. 40%, overall p=0.1 for bleeding type). Management of bleeding differed by anticoagulation type: blood products and reversal agents were more commonly used in patients on warfarin (Table). No patient received prothrombin complexes, recombinant factor VIIa, aminocaproic acid, tranexamic acid, aprotinin, or desmopressin. Out of 90 major bleeding events in NOAC patients, only 1 was fatal (1%). Within 30 days following bleeding, there were no strokes and 1 TIA (NOAC). Following a major bleed, the recurrent bleeding rate in NOAC patients in the next 30-days was 4% and the death rate was 4%. Conclusions: Rates of major bleeding with NOACs in clinical practice are comparable to those reported in clinical trials. Compared with warfarin, bleeding among NOAC users was less likely intracranial and more likely to be GI. Management of bleeding in the setting of NOAC rarely includes reversal agents.
Mutational status and metastatic patteRn in a cohort Of ADvanced colorectal cancer (aCRC) patients (pts): The ROAD study
Authors: E. Ongaro, G. De Maglio, L. Gerratana, M. Bonotto, S.K. Garattini, D. Basile, M. Cattaneo, V.J. Andreotti, F. Cortiula, A. Parnofiello, V. Fanotto, S. Pizzolitto, G.G. Cardellino, M. Casagrande, F. Puglisi, G. Aprile, N. Pella, G. Fasola
Journal: Annals of Oncology (2017)
Family-associated factors influence the postoperative prognosis in patients with non-small cell lung cancer
Authors: S. Takamori, G. Toyokawa, H. Ueo, F. Kinoshita, Y. Kozuma, T. Matsubara, N. Haratake, T. Akamine, F. Hirai, T. Tagawa, F. Shoji, T. Okamoto, Y. Maehara
Journal: Annals of Oncology (2017)
Enzymatic synthesis of core 2 O-glycans governs the tissue-trafficking potential of memory CD8 <sup>+</sup> T cells
Authors: Jossef F. Osborn, Jana L. Mooster, Samuel J. Hobbs, Michael W. Munks, Conrad Barry, John T. Harty, Ann B. Hill, Jeffrey C. Nolz
Journal: Science Immunology (2017)

Central memory CD8 + T cells are the major memory CD8 + T cell subset that traffics into inflamed, nonlymphoid tissues.
Safety and clinical activity of DS-6051b, a ROS1/NTRK inhibitor, in Japanese patients with NSCLC harboring ROS1 fusion gene
Authors: M. Takeda, T. Seto, Y. Fujiwara, N. Yamamoto, K. Nosaki, R. Toyozawa, C. Abe, R. Shiga, K. Nakamaru, K. Nakagawa
Journal: Annals of Oncology (2017)
GW28-e0546 QT Measurement in the Presence of Atrial Fibrillation: Minimizing the Effects of RR Fluctuations on QT Interval
Authors: Xiaojie Wang, Yunlong Xia, Xu Han, Binhao Wang, Yiheng Yang, Peter R. Kowey, Li Zhang
Journal: Journal of the American College of Cardiology (2017)
Submaximal Blood Pressure Responses to Exercise in Young Adulthood and Long-Term Cardiovascular Health
Authors: Ravi Shah, Venkatesh L. Murthy, Laura A. Colangelo, Jared P. Reis, J. Jeffrey Carr, Stephen Sidney, Juned Siddique, Cora E. Lewis, Joao A.C. Lima, Gregory D. Lewis
Journal: Journal of the American College of Cardiology (2017)
Outcomes of malignant pleural mesothelioma (MPM) patients (p) treated with immune-oncology drugs (IO) in clinical trials
Authors: S. Cedres, A. Martinez Marti, A. Navarro, N. Pardo, J. Remon, I. Matos, M. Ochoa de Olza, C. Hierro, J. Martin Liberal, J.M. Miquel, C. Viaplana, G. Villacampa Javierre, R. Dienstmann, E. Felip Font
Journal: Annals of Oncology (2017)
Armonización de los datos nacionales de morbilidad del EISS
Authors: H Uphoff, J M Cohen, D M Fleming, A Noone
Journal: Eurosurveillance (2003)

El Programa Europeo de Vigilancia de la Gripe (European Influenza Surveillance Scheme) es un proyecto de colaboracion en el que participan dieciocho paises miembros (2001/02), destinado a controlar la actividad y el impacto de la gripe mediante la recogida anual de datos virologicos y de morbilidad en los centros de atencion primaria durante la temporada invernal. Aunque en un principio es similar al concepto de vigilancia, los indicadores utilizados y las observaciones realizadas son muy distintas. Los distintos sistemas de atencion sanitaria y las necesidades de organizacion (como por ej., certificado medico para la empresa) influyen en el comportamiento de consulta. Ademas, y en parte como consecuencia de las diferencias entre los sistemas de atencion sanitaria, las definiciones utilizadas para el numerador y el denominador al calcular las tasas de morbilidad son diferentes. De ahi que la interpretacion comparativa de los datos de morbilidad de los paises participantes resulte extremadamente dificil. La 'armonizacion' de las declaraciones utilizando numeradores y denominadores equivalentes es una opcion, pero resulta dificil de lograr a corto plazo. Ademas, habria que tener en cuenta otros temas, como la necesidad de continuidad de la vigilancia y si tales pasos podrian, en efecto, dar lugar a una comparabilidad directa, etc. Se probo un indice sencillo que permite comparar el impacto de la morbilidad gripal en un ano dado con lo que se considera una epidemia 'habitual' en ese pais. Inicialmente, el indice describe numericamente la medida en que la morbilidad en exceso atribuible a la gripe en la epidemia en vigor en cada pais esta dentro, fuera o es inferior a un intervalo tipico de epidemia gripal. En este estudio piloto, la utilidad de este indice se analiza con el ejemplo de ocho paises en las temporadas 1999/2000 y 2000/01. Aun no se han perfeccionado los metodos.
Efficacy of palbociclib plus fulvestrant in advanced Hormone Receptor-positive (HR+) metastatic breast cancer (MBC) pretreated with everolimus: Real-life data from the french temporary authorization for use (TAU) at the Institut de Cancérologie de l’Ouest
Authors: P. Du Rusquec, C. Palpacuer, L. Campion, A. Patsouris, P. Augereau, C. Gourmelon, M. Robert, L. Dumas, C. Folliard, M. Campone, J-S. Frenel
Journal: Annals of Oncology (2017)
Calcium-Dependent Arrhythmogenic Foci Created by Weakly Coupled Myocytes in the Failing Heart
Authors: Di Lang, Daisuke Sato, Yanyan Jiang, Kenneth S. Ginsburg, Crystal M. Ripplinger, Donald M. Bers
Journal: Circulation Research (2017)

Rationale: Intercellular uncoupling and Ca 2+ (Ca) mishandling can initiate triggered ventricular arrhythmias. Spontaneous Ca release activates inward current which depolarizes membrane potential (V m ) and can trigger action potentials in isolated myocytes. However, cell-cell coupling in intact hearts limits local depolarization and may protect hearts from this arrhythmogenic mechanism. Traditional optical mapping lacks the spatial resolution to assess coupling of individual myocytes. Objective: We investigate local intercellular coupling in Ca-induced depolarization in intact hearts, using confocal microscopy to measure local V m and intracellular [Ca] simultaneously. Methods and Results: We used isolated Langendorff-perfused hearts from control (CTL) and heart failure (HF) mice (HF induced by transaortic constriction). In CTL hearts, 1.4% of myocytes were poorly synchronized with neighboring cells and exhibited asynchronous (AS) Ca transients. These AS myocytes were much more frequent in HF (10.8% of myocytes, P &lt;0.05 versus CTL). Local Ca waves depolarized V m in HF but not CTL hearts, suggesting weaker gap junction coupling in HF-AS versus CTL-AS myocytes. Cell-cell coupling was assessed by calcein fluorescence recovery after photobleach during intracellular [Ca] recording. All regions in CTL hearts exhibited faster calcein diffusion than in HF, with HF-AS myocyte being slowest. In HF-AS, enhancing gap junction conductance (with rotigaptide) increased coupling and suppressed V m depolarization during Ca waves. Conversely, in CTL hearts, gap junction inhibition (carbenoxolone) decreased coupling and allowed Ca wave-induced depolarizations. Synchronization of Ca wave initiation and triggered action potentials were observed in HF hearts and computational models. Conclusions: Well-coupled CTL myocytes are effectively voltage-clamped during Ca waves, protecting the heart from triggered arrhythmias. Spontaneous Ca waves are much more common in HF myocytes and these AS myocytes are also poorly coupled, enabling local Ca-induced inward current of sufficient source strength to overcome a weakened current sink to depolarize V m and trigger action potentials.
iASPP Is an Antioxidative Factor and Drives Cancer Growth and Drug Resistance by Competing with Nrf2 for Keap1 Binding
Authors: Wenjie Ge, Kunming Zhao, Xingwen Wang, Huayi Li, Miao Yu, Mengmeng He, Xuting Xue, Yifu Zhu, Cheng Zhang, Yiwei Cheng, Shijian Jiang, Ying Hu
Journal: Cancer Cell (2017)
Communication-and-Resolution Programs
Authors: Kathryn Zeiler
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Phosphatases in Mouse Mast Cells Rapid IgE Desensitization: The Role of SHIP-1
Authors: Leila A. Alenazy, Leticia de las Vecillas Sanchez, Teodorikez W. Jimenez Rodriguez, Cintia A. Falck-Fuentes, Mariana C. Castells
Journal: Journal of Allergy and Clinical Immunology (2018)
GW28-e0637 Interleukin 37 suppresses the M1 polarization of macrophages through Notch1 and Nuclear factor kappa B pathways
Authors: Qingchun Zeng, Qiong Ma, Wenhui Dong, Peitao Zhou, Suyu Zong, Shuwen Su, Xi Yang, Jiaying Li, Wenyan Lai, Dingli Xu
Journal: Journal of the American College of Cardiology (2017)
Randomized phase 2 trial of nab-paclitaxel plus gemcitabine, ± capecitabine, cisplatin (paxg regimen) in metastatic pancreatic adenocarcinoma
Authors: S. Zanon, C. Pircher, M. Chiaravalle, M. Macchini, U. Peretti, G. Balzano, P. Passoni, R. Nicoletti, P.G. Arcidiacono, G. Pepe, C. Doglioni, S. Romi, E. Gritti, M. Falconi, L. Gianni, M. Reni
Journal: Annals of Oncology (2017)
Circulating tumor cells as liquid biopsy for castration resistant prostate cancer patients treated with cabazitaxel
Authors: S. Salvi, V. Conteduca, V. Casadio, P. Fici, G. Gurioli, F. Martignano, U. Basso, G. Fornarini, C. Lolli, G. Schepisi, S. Testoni, D. Calistri, U. De Giorgi
Journal: Annals of Oncology (2017)
Sinonasal non-glandular cancers relapsing after multimodal treatments
Authors: S. Cavalieri, R. Granata, L.D. Locati, C. Bergamini, S. Alfieri, C. Resteghini, D. Galbiati, E. Orlandi, N.A. Iacovelli, G. Calareso, M. Guzzo, P. Quattrone, L. Licitra, P. Bossi
Journal: Annals of Oncology (2017)
Magnesium Intake, Quality of Carbohydrates, and Risk of Type 2 Diabetes: Results From Three U.S. Cohorts
Authors: Adela Hruby, Marta Guasch-Ferré, Shilpa N. Bhupathiraju, JoAnn E. Manson, Walter C. Willett, Nicola M. McKeown, Frank B. Hu
Journal: Diabetes Care (2017)

Magnesium intake is inversely associated with risk of type 2 diabetes in many observational studies, but few have assessed this association in the context of the carbohydrate quality of the diet. We hypothesized that higher magnesium intake is associated with lower risk of type 2 diabetes, especially in the context of a poor carbohydrate-quality diet characterized by low cereal fiber or high glycemic index (GI) or glycemic load (GL).In the Nurses' Health Study (NHS; 1984-2012, n = 69,176), NHS2 (1991-2013, n = 91,471), and the Health Professionals' Follow-Up Study (1986-2012, n = 42,096), dietary intake was assessed from food frequency questionnaires every 4 years. Type 2 diabetes was ascertained by biennial and supplementary questionnaires. We calculated multivariate hazard ratios (HRs) of magnesium intake and incident diabetes, adjusted for age, BMI, family history of diabetes, physical activity, smoking, hypertension, hypercholesterolemia, GL, energy intake, alcohol, cereal fiber, polyunsaturated fats, trans fatty acids, and processed meat, and we considered the joint associations of magnesium and carbohydrate quality on diabetes risk.We documented 17,130 incident cases of type 2 diabetes over 28 years of follow-up. In pooled analyses across the three cohorts, those with the highest magnesium intake had 15% lower risk of type 2 diabetes compared with those with the lowest intake (pooled multivariate HR in quintile 5 vs. 1: 0.85 [95% CI 0.80-0.91], P < 0.0001). Higher magnesium intake was more strongly associated with lower risk of type 2 diabetes among participants with high GI or low cereal fiber than among those with low GI or high cereal fiber (both P interaction <0.001).Higher magnesium intake is associated with lower risk of type 2 diabetes, especially in the context of lower carbohydrate-quality diets.
Lessons learnt from imported cases and onward transmission of Lassa fever in Europe support broader management of viral haemorrhagic fevers
Authors: Roger Hewson
Journal: Eurosurveillance (2017)

Preview this article: Lessons learnt from imported cases and onward transmission of Lassa fever in Europe support broader management of viral haemorrhagic fevers, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/22/39/eurosurv-22-39-1-1.gif
Single nucleotide polymorphisms in PD-L1 and outcome in nivolumab-treated advanced non-small-cell lung cancer patients
Authors: T. Nomizo, T. Funazo, H. Ozasa, T. Tsuji, Y. Yasuda, H. Yoshida, Y. Sakamori, H. Nagai, T. Hirai, Y.H. Kim
Journal: Annals of Oncology (2017)
SPAZO2 (SOGUG): Validation of the international metastatic database consortium (IMDC) prognostic classification for targeted therapies as 2nd-line after 1st-line pazopanib (1stPz) in metastatic renal cell carcinoma (mRC)
Authors: B. Pérez-Valderrama, J. Arranz Arija, I. Chirivella González, U. Anido Herranz, J.M. Jurado García, C. Suarez Rodriguez, I. García Carbonero, G. de Velasco, R. García Domínguez, R.D. García Marrero, M.A. Gonzalez Del Alba Baamonde, C. Molins Palau, M.E. Lazaro, J. Munoz-Langa, E. Martinez Ortega, A. Hernández Jorge, M. Campayo Guillaumes, M. Sereno Moyano, R. Luque Caro, Á. Rodríguez Sánchez
Journal: Annals of Oncology (2017)
Untreated hormone receptor positive/HER2-negative metastatic breast cancer survival with front-line chemotherapy and maintenance endocrine therapy
Authors: R. Sabatier, A. Meskine, M.A. Cappiello, J-M. Extra, C. Tarpin, F. Rousseau, M. Provansal, F. Bertucci, P. Viens, A. Gonçalves
Journal: Annals of Oncology (2017)